<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01811394</url>
  </required_header>
  <id_info>
    <org_study_id>ISAC-01</org_study_id>
    <nct_id>NCT01811394</nct_id>
  </id_info>
  <brief_title>Ion Irradiation of Sacrococcygeal Chordoma</brief_title>
  <acronym>ISAC</acronym>
  <official_title>Hypofractionated Ion Irradiation (Protons or Carbon Ions) of Sacrococcygeal Chordoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heidelberg University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Heidelberg University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and feasibility of primary
      hypofractionated irradiation of sacrococcygeal chordoma with carbon ions or protons using the
      raster scan technique.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this trial is safety and feasibility of hypofractionated irradiation
      in patients with sacrococcygeal chordoma using protons or carbon ions in raster scan
      technique for primary or additive treatment after R2 resection. The evaluation is therefore
      based on the proportion of treatments without Grade 3-5 toxicity (CTCAE, version 4.0) up to
      12 months after treatment and/or discontinuation of the treatment for any reason as primary
      endpoint. Local-progression free survival, overall survival and quality of life will be
      analyzed as secondary end points.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>safety and feasibility of hypofractionated irradiation in patients with sacrococcygeal chordoma using ions (protons or carbon ions) in raster scan technique</measure>
    <time_frame>From date of treatment start until 12 months after treatment.</time_frame>
    <description>The evaluation is based on incidence of Grade 3-5 toxicity (NCI-CTC-AE) and/or discontinuation of the treatment for any reason. Endpoint is the proportion of treatments without Grade 3-5 toxicity (NCI-CTC-AE) up to 12 months after treatment and/or discontinuation of the treatment for any reason</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>local progression free survival (LPFS)</measure>
    <time_frame>From date of treatment start until the date of first documented progression in MRI/CT scan assessed up to 12 months.</time_frame>
    <description>local progression free survival (LPFS) is determined from start of treatment until local progression in imaging (&gt;10% size increase)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>From date of treatment start until the date of death from any cause assessed up to 12 months.</time_frame>
    <description>Further objectives are overall survival (OS) from date of treatment start until the date of death from any cause assessed up to 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (QoL)</measure>
    <time_frame>From date of treatment start up to 12 months. Evaluation at treatment start, at the end of treatment and 12 months after treatment.</time_frame>
    <description>Quality of life (QoL) evaluated with EORTC-QLQ30 questionnaire.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Sacral Chordoma</condition>
  <arm_group>
    <arm_group_label>protons</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>16x4GyE protons</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Carbon ions</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>16x4GyE carbon ions</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>protons</intervention_name>
    <description>Treatment is performed using 16 x 4 GyE protons</description>
    <arm_group_label>protons</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>carbon ions</intervention_name>
    <description>Treatment is performed using 16 x 4 GyE carbon ions</description>
    <arm_group_label>Carbon ions</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histological confirmation of sacrococcygeal chordoma

          -  Karnofsky performance status ≥ 70%

          -  Patients age 18 - 80 years

          -  Macroscopic tumour (MRI)

          -  Written informed consent

        Exclusion Criteria:

          -  Lack of macroscopic tumour

          -  Tumor extension in craniocaudal direction &gt;16cm

          -  Metal implants at the level of the tumor which could influence the treatment planning

          -  Inability of the patient to lie quiet for at least 20 minutes (eg due to pain)

          -  Prior radiotherapy of the pelvic region

          -  Simultaneous participation in another trial that could influence the results of the
             study

          -  Active medical implants without treatment approval at the time of ion irradiation (eg,
             cardiac pacemaker, defibrillator)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Matthias Uhl, Dr.</last_name>
    <phone>+49 6221 568201</phone>
    <email>Matthias.uhl@med.uni-heidelberg.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Klaus Herfarth Herfath, Prof.Dr.</last_name>
    <phone>+49 6221 568201</phone>
    <email>Klaus.herfarth@med.uni-heidelberg.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Heidelberg, Radiooncology, HIT</name>
      <address>
        <city>Heidelberg</city>
        <zip>69125</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthias Uhl, Dr.</last_name>
      <phone>+49 6221 568201</phone>
      <email>Matthias.uhl@med.uni-heidelberg.de</email>
    </contact>
    <contact_backup>
      <last_name>Klaus Herfarth, Prof.Dr.</last_name>
      <phone>+49 6221 568201</phone>
      <email>Klaus.herfarth@med.uni-heidelberg.de</email>
    </contact_backup>
    <investigator>
      <last_name>Klaus Herfarth, Prof.Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Uhl M, Edler L, Jensen AD, Habl G, Oelmann J, Röder F, Jäckel O, Debus J, Herfarth K. Randomized phase II trial of hypofractionated proton versus carbon ion radiation therapy in patients with sacrococcygeal chordoma-the ISAC trial protocol. Radiat Oncol. 2014 Apr 29;9:100. doi: 10.1186/1748-717X-9-100.</citation>
    <PMID>24774721</PMID>
  </reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 9, 2013</study_first_submitted>
  <study_first_submitted_qc>March 12, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 14, 2013</study_first_posted>
  <last_update_submitted>May 1, 2017</last_update_submitted>
  <last_update_submitted_qc>May 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Heidelberg University</investigator_affiliation>
    <investigator_full_name>Klaus Herfarth, MD</investigator_full_name>
    <investigator_title>Prof. Dr.</investigator_title>
  </responsible_party>
  <keyword>sacral chordoma</keyword>
  <keyword>chordoma</keyword>
  <keyword>carbon ion therapy</keyword>
  <keyword>proton therapy</keyword>
  <keyword>hypofractionation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chordoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

